Last reviewed · How we verify
Phenylephrine 1.0%/ Ketorolac 0.3%
This combination ophthalmic drop uses phenylephrine to constrict blood vessels and reduce redness while ketorolac provides anti-inflammatory and analgesic effects.
This combination ophthalmic drop uses phenylephrine to constrict blood vessels and reduce redness while ketorolac provides anti-inflammatory and analgesic effects. Used for Ocular redness and irritation associated with allergic conjunctivitis or post-operative inflammation.
At a glance
| Generic name | Phenylephrine 1.0%/ Ketorolac 0.3% |
|---|---|
| Sponsor | University of Florida |
| Drug class | Combination ophthalmic decongestant and NSAID |
| Target | Alpha-1 adrenergic receptor (phenylephrine); COX-1 and COX-2 (ketorolac) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Phenylephrine is an alpha-1 adrenergic agonist that causes vasoconstriction of conjunctival blood vessels, reducing ocular hyperemia and redness. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin-mediated inflammation and pain. Together, they address both the vascular and inflammatory components of ocular irritation and redness.
Approved indications
- Ocular redness and irritation associated with allergic conjunctivitis or post-operative inflammation
Common side effects
- Ocular irritation or stinging
- Conjunctival blanching
- Rebound hyperemia
- Systemic absorption effects (tachycardia, hypertension)
Key clinical trials
- Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC (PHASE1, PHASE2)
- Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3% (EARLY_PHASE1)
- Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phenylephrine 1.0%/ Ketorolac 0.3% CI brief — competitive landscape report
- Phenylephrine 1.0%/ Ketorolac 0.3% updates RSS · CI watch RSS
- University of Florida portfolio CI